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Background: An elevated uric acid (UA) level is associatedwith an increased risk of adverse outcomes in patients
with chronic heart failure (CHF). Febuxostat and allopurinol lower the UA levels and attenuate the expression of
an inﬂammatory marker, monocyte chemoattractant protein (MCP)-1. However, a direct comparison of the ef-
fects of febuxostat and allopurinol on the inﬂammation and cardiac function in CHF patients with hyperuricemia
has not yet been performed.
Methods: A total of 61 CHF patients with hyperuricemia who had a mean left ventricular ejection fraction (LVEF)
of 37.1 ± 6.7% were randomly assigned to receive febuxostat (n = 31) or allopurinol (n = 30).
Results: The MCP-1 levels and LVEF at baseline were comparable between the groups. However, after 12 months
of treatment, the febuxostat group achieved signiﬁcantly higher percent decreases in the UA and MCP-1 levels
from baseline than those of the allopurinol group (p b 0.001). The LVEF in both groups had improved after 12
months; however, a greater percent increase in the LVEF from baseline was observed in the febuxostat group
than that in the allopurinol group (p b 0.001). The percent increase in the LVEF from baseline was found to be
signiﬁcantly associated with the percent decrease in MCP-1 (r =−0.634, p b 0.001) in the febuxostat group.
Conclusions: These data indicate that febuxostat is more effective than allopurinol in reducing the UA level and
inﬂammation and may improve the cardiac function in CHF patients with hyperuricemia due, at least in part,
to reductions in inﬂammation.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Uric acid (UA) is the end-product of purine metabolism in the
human body [1]. Earlier studies have shown that heart failure is often
associated with hyperuricemia, and an elevated serum UA level is
associated with an increased risk of incident heart failure and adverse
outcomes in patients with chronic heart failure (CHF) [2–4].
Inﬂammation plays an important role in the pathogenesis of CHF.
Monocyte chemoattractant protein (MCP)-1 has been implicated in
the pathogenesis and progression of heart failure as a mediator of myo-
cardial dysfunction and remodeling [5–7]. Furthermore, the myocardial
MCP-1 level is upregulated in rats with volume-overload heart failure,
suggesting that MCP-1 plays important roles in the pathogenesis and
exacerbation of CHF [8]. In addition, UA stimulates the production of
MCP-1 via the activation of the mitogen-activated protein kinase
(MAPK) and cyclooxygenase-2 (COX-2) pathways [9].y 206-8512, Tokyo, Japan.
land Ltd. This is an open access articlThe activation of MCP-1 induces monocyte-mediated inﬂammation,
aswell as the production of adhesionmolecules and inﬂammatory cyto-
kines, thus resulting in endothelial dysfunction [10]. Endothelial dys-
function plays an important role in the pathogenesis of cardiovascular
diseases, including CHF [11,12]. Nitric oxide (NO) is a molecule known
to protect the endothelial function. Asymmetric dimethylarginine
(ADMA)was recently found to be as an endogenous, competitive inhib-
itor ofNO synthetase and it is now considered to be a novel independent
risk factor for endothelial dysfunction. In addition, elevated plasma
levels of ADMA have been reported to be independent predictors of
poor outcomes in patients with CHF [13,14]. Therefore, inﬂammation
associated with endothelial dysfunction may play a crucial role in the
pathogenesis and exacerbation of CHF.
Cystatin C (CysC) and urinary microalbumin (Ualb) are novel and
stable biomarkers of the renal function and endothelial dysfunction.
Recent studies have shown that both the CysC and Ualb levels are
independent predictors of cardiovascular diseases, including CHF [15,16].
Eicosapentaenoic acid (EPA) is a long-chain omega-3 polyunsaturated
fatty acid (PUFA) isolated from ﬁsh oil, and arachidonic acid (AA) is thee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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substrates for COX and lipoxygenase, which are involved in the
production of eicosanoids [17]. It was previously reported that the
EPA/AA ratio is signiﬁcantly associated with the risk of cardiovascular
diseases, including CHF [18,19].
Recent studies have shown that febuxostat, a novel non-purine se-
lective inhibitor of xanthine oxidase (XO), is more effective than allopu-
rinol in lowering the UA levels in patients with hyperuricemia and gout
[20,21]. Febuxostat and allopurinol both attenuate the production of
MCP-1 in monocytes [22,23]. Hirsch et al. showed that allopurinol
acutely increased the adenosine triphosphate (ATP) energy delivery in
the failing heart [24]. In addition, Xu et al. reported that febuxostat at-
tenuated systolic overload-induced left ventricular hypertrophy and
dysfunction inmice [25]. These data suggest that febuxostat and allopu-
rinol may confer beneﬁts for patients with CHF and hyperuricemia.
However, no previous studies have performed a direct comparison of
the effects of febuxostat and allopurinol on inﬂammation and the cardi-
ac function in CHF patients with hyperuricemia. The aim of the present
study was therefore to directly compare these agents.
2. Methods
2.1. Patient population
A total of 66 selected (non-consecutive) patientswith CHF (39males
and 27 females; mean age, 71.5 ± 8.4 years) who had a mean left ven-
tricular ejection fraction (LVEF) of 37.0 ± 6.8% with hyperuricemia
(serum UA level ≥ 8.0 mg/dL) were enrolled in the current study
(Fig. 1). All patientswere recruited fromTama-NagayamaHospital, Nip-
pon Medical School, at an outpatient clinic between September 2011
and April 2013. Follow-up data were obtained every four to eight
weeks via direct contact with the patients at an outpatient clinic of
our hospital or telephone contact with the nine patients who moved
to other hospitals until June 2015.
The etiology of CHF was dilated cardiomyopathy (DCM) in 18
patients and ischemic cardiomyopathy (ICM) in 48 patients. DCM was
deﬁned as a normal coronary arteriogram together with severe
hypokinesis of the left ventricular wall motion as determined on left
ventriculography, and according to typical pathological ﬁndings of an
endomyocardial biopsy of the left ventricle. ICMwasdeﬁned as a history
of myocardial infarction with signiﬁcant coronary artery disease (N70%
luminal stenosis in at least two major coronary arteries).
The LVEF wasmeasured using echocardiographywith a LOGIQ 7 de-
vice (GE; Milwaukee, WI) within one week of measuring the biochem-
ical markers. The patients were placed in the left lateral recumbentFig. 1. A schematic diagram of the trial. The details of this trial are described in the text
(Study population and protocol).position, and the LVEFwas calculated according to the Simpsonmethod
using apical four and two-chamber views. All echocardiograms of the el-
igible patientsweremeasured at baseline and after six and 12months of
treatment and analyzed by two blinded trained cardiologists.
The end-diastolic left ventricular (LV) diameter (LVDd), end-
diastolic thickness of the ventricular septum (VST) and end-diastolic
thickness of the LV posterior wall (PWT) were measured by M-mode
echocardiography. By using these parameters, the LVmasswas calculat-
ed according to the recommendations of the American Society of Echo-
cardiography [26] and normalized for the body surface area (LV mass
index: g/m2 where LVmass (g)= 0.8 × 1.04 [(LVDd+ PWT+VST)3−
(LVDd)3] + 0.6). The LVmass index wasmeasured at baseline and after
12 months of treatment.
We enrolled CHF patients who had been stabilized using standard
medical treatment for CHF, as follows: all eligible patients had received
standard medical treatment, including angiotensin-converting enzyme
inhibitors (ACEIs), angiotensin receptor II blockers (ARBs), β-blockers,
furosemide, spironolactone or any combination thereof for at least
three years prior to enrollment in the present study. None of the pa-
tients had received any anti-hyperuricemic medications prior to enroll-
ment in the present study, and no patients received any additional
treatment for CHF during the follow-up period.
All patients with clinical signs of acute infection, autoimmune disor-
ders, severe renal disease (an estimated glomerular ﬁltration rate
(eGFR) b30 mL/min/1.73 m2) or hepatic disease and those with
suspected malignancy were excluded from the present series. In addi-
tion, all patients in the acute decompensated stage of CHFwere exclud-
ed from the present study.
2.2. Study protocol
This study was a prospective, randomized and open-label study. The
present study was originally designed to enroll more than 400 patients,
because 200 patients were required in each group in order to achieve a
power of 80% to detect a 20% difference in the percent changes in the UA,
and the mean LVEF and LV mass index from baseline to 12 months of
treatment between the treatment groups. For equalization between the
two groups, the patientswere randomly assigned to either the febuxostat
group or the allopurinol group. The envelope method was employed
using mathematical techniques, such as the use of a random number
table by an independent administrator (Y.S.) for group allocation. The
present study does not have a study registration number or URL.
The investigation protocol was approved by the institutional ethics
committee of Tama-Nagayama Hospital, Nippon Medical School and
was carried out in accordance with the Declaration of Helsinki. All se-
lected eligible patients provided their written informed consent to par-
ticipate in the study.
Five patients were excluded from randomization because of non-
compliance or withdrawal of consent. Then, 31 of the 61 remaining pa-
tientswere randomly assigned to receive from10 to 40mgof febuxostat
per day (Teijin Pharma, Tokyo, Japan), while the remaining 30 patients
were randomly assigned to receive from 100 to 300 mg of allopurinol
per day. Initially, we could not follow-up ﬁve patients treated with
febuxostat and four patients treated with allopurinol because they
moved to other hospitals during the follow-up period. Therefore,
twenty-six patients treated with febuxostat and 26 patients treated
with allopurinol ﬁnished the present study. However, we asked the re-
ferring doctors to send the missing data to us, including the laboratory
and echocardiographic ﬁndings, andwewere able to obtain all informa-
tion on the nine patents that moved to other hospitals. Finally, we
reanalyzed the data and thus 31 patients treated with febuxostat and
30 patients treated with allopurinol were included in the ﬁnal analyses.
The target serum UA level was ≤6.0 mg/dL. The initial doses of
febuxostat and allopurinol were 10 mg/day and 100 mg/day, respec-
tively. The dose of the medication was increased up to a maximum of
40 mg/day for febuxostat and 300 mg/day for allopurinol. The dose of
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randomized to allopurinol, those with a normal renal function (eGFR
≥90 mL/min/1.73 m2) or mild renal impairment (eGFR: 60–89 mL/min/
1.73 m2) received a maximum dose of up to 300 mg/day of allopurinol,
and those with moderate renal impairment (eGFR: 30–59 mL/min/
1.73 m2) received a maximum dose of up to 200 mg/day of allopurinol.
2.3. Laboratory measurements
The serum levels of MCP-1 at baseline and after 12 months of treat-
ment were measured with a speciﬁc enzyme-linked immunosorbent
assay (ELISA) using a commercially available system (R&D Systems),
and the results are expressed as the mean ± SD (pg/mL). The intra-
and inter-assay coefﬁcients of variation were less than 5% for all ELISAs,
and all samples were analyzed in duplicate.
The high-sensitivity C-reactive protein (hsCRP) levels were mea-
sured using an immunoturbidimetry assay. The plasma B-type natri-
uretic peptide (BNP) concentrations were determined with a speciﬁc
immunoradiometric assay for human BNP using commercial kits
(Shionoria Kit, Shionogi and Kyowa Medex, Tokyo, Japan). The perfor-
mance characteristics of the Shionoria BNP kit include a coefﬁcient of
variation of 2.5–4.3% (n = 10) with an analytical range of 4–
2000 pg/mL.
To determine the renal function, the eGFR was calculated according
to the following equation for Japanese subjects, as recommended by the
Japanese Society of Nephology: eGFR (mL/min/1.73m2)=194 × serum
creatinine−1.094 (mg/dL)×Age−0.287 (years) × 0.739, if female [27]. The
plasma levels of CysC were measured by the N Latex Cystatin C assay
(Date-Behring, Deerﬁeld, IL), a latex-enhanced nephelometric immuno-
assay using rabbit polyclonal antibodies. The Ualb levels weremeasured
using a nephelometric method on the Date Behring BN100. The intra-
and inter-assay coefﬁcients of variation were b2.0%.
The plasma levels of ADMAweremeasured using high-performance
liquid chromatography (HPLC) with ortho-phthalaldehyde for ﬂuores-
cence determination (SRL, Tokyo, Japan). Brieﬂy, HPLC was performed
on a Hitachi L-7100 system equipped with a Jasco FP-2025 ﬂuorescence
detector for excitation at 348 nm and emission at 450 nm with a
PEGASIL ODS (4.6 nm i.d. × 250 mm; Chemical Inspection and Testing
Institute). The samples were eluted with 75 mmol/l of aqueous acetate
buffer.
The serum levels of EPA and AA in fasting blood samples were mea-
sured at SRL Co., Ltd. (Tokyo, Japan). In brief, total lipids were extracted
according to the Folch method, and the fatty acids were then directly
transmethylated with a 14% boron triﬂuoride methanol solution
(Sigma-Aldrich Japan, Tokyo, Japan) at 90 °C for 90 min. The fatty acid
levels were measured using a GC-FID system (6890N; Agilent Technol-
ogies, Tokyo, Japan) equipped with a fused silica capillary column
(Omegamax 250, 30 m × 0.25 mm i.d.; 0.25 μm ﬁlm thickness; Supelo,
USA),with tricosenoic acid (C23:0)methyl ester as an internal standard.
The injector and detector temperatures were both set at 270 °C, and the
column temperature was held at 205 °C. Heliumwas used as the carrier
gas at a ﬂow rate of 2.0 mL/min. The split ratio was 50:1.
2.4. Follow-up and determination of outcomes
The outcome data were collected via serial direct contact visits with
the patients (every four to eight weeks) at an outpatient clinic of Tama-
Nagayama Hospital, Nippon Medical School or telephone contact with
nine patients whomoved to other hospitals until June 2015. All patients
were followed up for amedian of 23.0months (range: 13 to 47months)
to determine the incidence of cardiac events, such as cardiac death and
readmission due to aworsening of CHF. The primary endpointswere the
serumUA levels and the LVEF after treatment. The UA levels were mea-
sured at baseline (before treatment), and after one, three, six and 12
months of treatment. The LVEF was measured at baseline and after six
and 12months of treatment. The secondary endpoints included cardiacevents (cardiac death and readmissions due to aworsening of CHF), sys-
tolic blood pressure (SBP), heart rate, New York Heart Association
(NYHA) class and blood chemical variables (eGFR, CysC, Ualb, EPA/AA
ratio and BNP, ADMA and MCP-1 levels), the left ventricular (LV) mass
index and the proportion of patients in each treatment group with
serum UA b6.0 mg/dL after six and 12 months of treatment.
2.5. Statistical analysis
The results are presented as themean± SD for continuous variables
and the percentage of the total number of patients for categorical vari-
ables. Student's t-test for independent samples and the chi-square test
were used for comparisons of continuous and categorical variables, re-
spectively. The MCP, ADMA, triglyceride and hsCRP values and EPA/AA
ratio exhibited skewed distributions; therefore, the Mann–Whitney U
test was used for unpaired comparisons between groups, and
Wilcoxon's signed-rank test was used for paired comparisons within
groups. The bivariate correlations between parameters were assessed
with the Pearson or Spearman correlation (r) coefﬁcient for normal or
skewed distributions, respectively. For the time-course analysis, a
repeated-measures ANOVA with Fisher's protected least squares differ-
ence test was used.
Kaplan–Meier survival curves were used to assess the patients treat-
ed with febuxostat (febuxostat group) or allopurinol (allopurinol
group), and differences between the curves were evaluated with the
log-rank test. The treatment effect on the study endpoint (secondary
endpoint) was analyzed by a Cox proportional-hazards analysis, and
the hazard ratio (HR) with a 95% conﬁdence interval (CI) was calculat-
ed. The Statistical Package for Social Sciences (SPSS) for Windows, ver-
sion 22.0 (IBM, Japan) software package was used for all statistical
analyses. A value of p b 0.05 was considered to be statistically
signiﬁcant.
3. Results
3.1. Study population
Ultimately, 31 patients treated with febuxostat and 30 patients
treated with allopurinol completed the present study (Fig. 1). Of the
61 patients with CHF and hyperuricemia, six patients received 10 mg
of febuxostat, 19 patients received 20 mg of febuxostat, six patients re-
ceived 40 mg of febuxostat, eight patients received 100 mg of allopuri-
nol, 13 patients received 200 mg of allopurinol and nine patients
received 300 mg of allopurinol. None of the patients discontinued
febuxostat or allopurinol during the follow-up period.
The baseline clinical characteristics of the patients treated with
febuxostat and allopurinol are shown in Table 1. The patients treated
with febuxostat exhibited signiﬁcantly higher high-density lipoprotein
(HDL) cholesterol levels than those treated with allopurinol (p =
0.025); however, there were no signiﬁcant differences between the
groups in terms of the patient's age, gender, baseline body mass index
(BMI), systolic blood pressure (SBP), heart rate, the etiology of heart
failure (ischemic or dilated cardiomyopathy) or the prevalence of coro-
nary risk factors (Table 1). The baseline blood chemical variables of the
randomized patients were similar between the groups (Table 1). In ad-
dition, the prevalence of concomitant medicationswas also comparable
between the groups (Table 1).
3.2. Primary endpoints
The primary endpoints were the serum UA levels and the LVEF after
treatment. Themean baseline UA levels and LVEF were 9.4± 0.5 mg/dL
and 35.9 ± 7.3% in the febuxostat group and 9.3 ± 0.5 mg/dL and
38.4 ± 5.9% in the allopurinol group, respectively (UA: p = 0.895,
LVEF: p = 0.109, Table 2). The UA levels in the patients treated with
febuxostat and allopurinol were both signiﬁcantly reduced from
Table 1
Baseline clinical characteristics and blood chemistry parameters in CHF patients treated
with febuxostat and allopurinol.
Febuxostat
(n = 31)
Allopurinol
(n = 30)
p-Value
Age (years) 69.3 ± 10.0 71.8 ± 8.0 0.287
Gender (male, %) 22 (71.0) 18 (69.0) 0.786
Body mass index (kg/m2) 23.6 ± 2.4 23.1 ± 3.1 0.482
ICM/DCM 20/11 24/6 0.235
Hypertension (%) 27 (87.1) 30 (100.0) 0.113
Diabetes (%) 9 (29.0) 12 (40.0) 0.426
Dyslipidemia (%) 30 (96.8) 29 (96.7) 0.981
Active smoker (%) 6 (19.4) 4 (13.3) 0.731
Systolic blood pressure (mm Hg) 125 ± 10 126 ± 9 0.608
Heart rate (beats/min) 75 ± 5 74 ± 5 0.430
Hemoglobin (g/dL) 12.8 ± 1.2 13.1 ± 1.3 0.443
High sensitivity-C-reactive protein
(mg/L)
1.33 (1.06,
1.81)
1.37 (1.116,
1.71)
0.874
B-type natriuretic peptide (pg/mL) 210.4 ± 105.5 206.3 ± 105.4 0.880
Total cholesterol (mg/dL) 194 ± 14 189 ± 13 0.161
LDL-cholesterol (mg/dL) 117 ± 12 116 ± 10 0.869
HDL-cholesterol (mg/dL) 47 ± 6 43 ± 7 0.025
Triglycerides (mg/dL) 153 (148, 161) 152 (144, 158) 0.874
Fasting plasma glucose (mg/dL) 100 ± 10 104 ± 15 0.131
HbA1c (%, NGSP) 5.6 ± 0.3 5.7 ± 0.5 0.443
eGFR (mL/min/1.73 m2) 55.9 ± 10.2 58.8 ± 10.6 0.126
Baseline MCP-1 (pg/mL) 317.4 ± 60.1 341.3 ± 55.1 0.110
Left ventricular ejection fraction
(LVEF; %)
35.9 ± 7.3 38.4 ± 5.9 0.145
EPA/AA ratio 0.29 (0.24,
0.33)
0.25 (0.21, 0.33) 0.597
ADMA (μmol/mL) 0.57 (0.55,
0.62)
0.55 (0.52, 0.59) 0.082
Angiotensin converting inhibitor
use (%)
17 (54.8) 15 (50.0) 0.800
Angiotensin receptor blocker use
(%)
14 (45.2) 15 (50.0) 0.800
β-Blocker use (%) 29 (93.5) 24 (80.0) 0.147
Calcium channel blocker use (%) 2 (6.5) 1 (3.3) 0.537
Aspirin use (%) 27 (87.1) 30 (100.0) 0.113
Clopidogrel use (%) 9 (29.0) 7 (23.3) 0.772
Furosemide use (%) 17 (54.8) 16 (53.3) 0.906
Spironolactone use (%) 8 (25.8) 10 (33.3) 0.582
Statin use (%) 9 (29.0) 7 (23.3) 0.772
Data are expressed as the mean ± SD or medians (interquartile range), ICM: ischemic
cardiomyopathy, DCM: dilated cardiomyopathy, LDL: low-density lipoprotein, HDL;
high-density lipoprotein, NGSP: National Glycohemoglobin Standardization Program,
eGFR: estimated glomerular ﬁltration rate, MCP: monocyte chemoattractant protein,
EPA: eicosapentaenoic acid, AA: arachidonic acid and ADMA: asymmetric
dimethylarginine.
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(p b 0.001); however, the UA levels were signiﬁcantly lower in the
febuxostat group than those in the allopurinol group (each time point:
p b 0.001, Table 3). The percent changes in the UA levels from baseline
to 12 months were signiﬁcantly higher in the febuxostat group than
those in the allopurinol group (−40.3% vs.−33.5%, p b 0.001, Table 2).
The baseline LVEFwas comparable between the febuxostat and allo-
purinol groups (35.9 ± 7.3% vs. 38.4 ± 5.9%, p= 0.145, Tables 1 and 2).
The LVEF in both groups slightly improved after 12 months of treat-
ment, and the LVEF at 12 months was comparable between the groups
(41.7 ± 7.6% vs. 38.8 ± 8.2%, respectively, p = 0.161, Fig. 2, Tables 2
and 3), however, the LVEF in the febuxostat group had signiﬁcantly
improved after six and 12 months of treatment (six months: from
35.9 ± 7.3% to 36.8 ± 7.3%, p = 0.002, 12 months: from 35.79 ± 7.3%
to 41.7 ± 7.6%, p b 0.001, Fig. 2, Tables 2 and 3) but this was not ob-
served in the allopurinol group (six months: p = 0.071, 12 months:
p = 0.731, Fig. 2).
The most notable ﬁnding was that a greater percent increase in the
LVEF from baseline was observed in the febuxostat group than that in
the allopurinol group (+18.3% vs. +1.1%, p b 0.001, Table 2). These
data suggest that febuxostat treatment may improve the cardiac func-
tion in patients with CHF and hyperuricemia, but allopurinol does not.3.3. Secondary endpoints
The secondary endpoints included cardiac events (cardiac death and
readmissions due to a worsening of CHF), the SBP, heart rate, NYHA
class and blood chemical variables (eGFR, CysC, Ualb, EPA/AA ratio and
BNP, ADMA and MCP-1 levels), the LV mass index and the proportion
of patients in each treatment group with serum UA b6.0 mg/dL after
six and 12 months of treatment.
The SBP, heart rate and eGFR in the two groups after three, six and12
months of treatment are shown in Tables 2 and 3. There were no signif-
icant differences between the two groups in terms of the SBP at baseline
or after three, 6 months and 12 months of treatment. The SBP in both
groups signiﬁcantly decreased from baseline to each time point (each:
p b 0.01, Table 3).
The heart rate at 12months in the febuxostat groupwas signiﬁcantly
lower than that in the allopurinol group; however, therewere no signif-
icant differences between the two groups with respect to the heart rate
at baseline and after three and sixmonths of treatment. The percent de-
crease in the heart rate from baseline to 12 months was signiﬁcantly
higher in the febuxostat group than that in the allopurinol group
(−10.2% vs.−4.3%, p = 0.003, Table 2). The eGFR at baseline and at
each time point were comparable between the two groups. However,
the percent decrease in the eGFR from baseline to 12monthswas signif-
icantly higher in the allopurinol group than that in the febuxostat group
(−4.9% vs. +0.8%, p = 0.013, Table 2).
The CysC levels at baseline and after six and 12months of treatment
were similar between the two groups; however, the percent increase in
the CysC level from baseline to 12 months was signiﬁcantly higher in
the allopurinol group than that in the febuxostat group (+6.1% vs.
−0.9%, p = 0.010, Tables 2 and 3). In addition, the CysC levels after
six and 12 months of treatment in the allopurinol group were both sig-
niﬁcantly increased compared to those at baseline (p b 0.05, Table 3).
The baseline Ualb levels and those after six and 12months of treatment
were comparable between the two groups, however, the percent de-
crease in the Ualb from baseline to 12 months was signiﬁcantly higher
in the febuxostat group than that in the allopurinol group (−31.0% vs.
−5.6%, p = 0.006, Tables 2 and 3).
The prevalence of NYHA class at baseline and at 12monthswas sim-
ilar between the two groups (Table 2). However, at 12 months, among
the patients receiving allopurinol, seventeen (56.7%) remained in the
same NYHA class, whereas six patients (20.0%) increased their NYHA
class, suggesting that there was a worsening of the clinical status in
some patients. In the febuxostat group, seventeen patients (54.8%)
maintained their initial NYHA class, whereas nine patients (29.0%)
were assigned to a lower NYHA class and only one patient was assigned
to a higher NYHA class, indicating a functional improvement in some
patients. When compared with the initial NYHA class, these changes
were statistically signiﬁcant in the febuxostat group (p = 0.001), but
not in the allopurinol group (p = 0.183).
The baseline EPA/AA ratio and the BNP, ADMA and MCP-1 levels
were comparable between the two groups (Tables 1 and 2). The percent
increase in the EPA/AA ratio frombaseline to 12monthswas signiﬁcant-
ly higher in the febuxostat group than that in the allopurinol group
(+22.4% vs. +8.2%, p= 0.043, Table 2). Similarly, the percent decrease
in the BNP, ADMA and MCP-1 levels from baseline to 12 months was
signiﬁcantly higher in the febuxostat group than that in the allopurinol
group (BNP:−14.9% vs. +30.9%, p = 0.004, ADMA:−6.8% vs.−0.7%,
p = 0.007, MCP-1:−13.6% vs.−3.8%, p = 0.032, Table 2).
The baselineUA levelswere similar between the two groups, and the
proportions of patients with UA b 6.0 mg/dL at six and 12months were
signiﬁcantly higher in the febuxostat group than those in the allopurinol
group (6 months: 67.7% vs. 26.7%, p = 0.002, 12 months: 71.0% vs.
43.3%, p = 0.040).
The LVmass index at baseline and after 12months of treatmentwas
similar between the groups (Table 2). However, the percent decrease in
the LVmass index frombaseline to 12months tended to behigher in the
Table 2
Changes in the clinical characteristics and blood chemistry parameters from baseline to after 12 months of treatment in patients treated with febuxostat and allopurinol.
Febuxostat (n = 31) Allopurinol (n = 30)
Baseline 12 months (% change) Baseline 12 months (% change)
Body mass index (kg/m2) 23.6 ± 2.4 23.3 ± 2.2 (−0.9) 23.1 ± 3.1 22.8 ± 3.0 (−1.1)
Systolic BP (mm Hg) 125 ± 10 122 ± 10 (−2.9)* 126 ± 9 123 ± 9 (−2.5)*
Heart rate (beats/min) 75 ± 5 67 ± 7 (−10.2)** 74 ± 5 71 ± 5 (−4.3)$,&
NYHA class (I/II/III/IV) 0/26/5/0 9/17/5/0** 0/29/1/0 6/17/7/0
LVEF (%) 35.9 ± 7.3 41.7 ± 7.6 (+18.4)** 38.4 ± 5.9 38.8 ± 8.2 (+1.1)##
LV mass index (g/m2) 112.5 ± 21.0 104.2 ± 18.8 (−6.8)* 109.2 ± 19.6 105.9 ± 17.3 (−2.3)
Uric acid (mg/dL) 9.4 ± 0.5 5.6 ± 0.5 (−40.3)** 9.3 ± 0.5 6.2 ± 0.6 (−33.5)**
eGFR (mL/min/1.73 m2) 55.9 ± 10.2 56.7 ± 12.0 (+0.8) 58.8 ± 10.6 56.5 ± 14.6 (−4.9)&
Cystatin-C (mg/dL) 1.50 ± 0.32 1.49 ± 0.40 (−0.9) 1.43 ± 0.36 1.54 ± 0.51 (+6.1)$,&
Urinary albumin (μg/mg·Cr) 190.6 ± 162.7 134.1 ± 125.5 (−31.0)** 199.6 ± 161.0 199.5 ± 178.1 (−5.6)#
BNP (pg/mL) 210.4 ± 105.5 202.8 ± 198.1 (−14.9)$ 204.6 ± 106.2 270.1 ± 200.1 (+30.9)*,#
hsCRP (mg/L) 1.33 (1.06, 1.81) 1.06 (0.92, 1.58) (−15.2)** 1.37 (1.11, 1.64) 1.28 (0.99, 1.56) (−9.2)*,#
Total cholesterol (mg/dL) 194 ± 14 186 ± 13 (−4.0)** 189 ± 13 183 ± 11 (−3.2)**
LDL cholesterol (mg/dL) 117 ± 12 115 ± 10 (−1.6) 116 ± 10 115 ± 8 (−0.6)
HDL cholesterol (mg/dL) 47 ± 6 46 ± 6 (−0.7) 43 ± 7 43 ± 8 (−0.3)
Triglycerides (mg/dL) 153 (148, 160) 126 (114, 132) (−17.1)** 152 (144, 158) 128 (108, 135) (−16.4)**
MCP-1 (pg/mL) 306.0 (272.0, 375.0) 249.5 (208.8, 315.3) (−13.6)* 351.0 (298.0, 375.0) 315.5 (265.3, 433.0) (−3.8)$,&
EPA/AA ratio 0.29 (0.24, 0.33) 0.35 (0.32, 0.37) (+22.4)** 0.25 (0.21, 0.33) 0.27 (0.19, 0.34) (+8.2)&
ADMA (μmo/mL) 0.55 (0.53, 0.61) 0.54 (0.47, 0.60) (−6.8)** 0.55 (0.52, 0.61) 0.55 (0.50, 0.60) (−0.7)#
$p b 0.05, *p b 0.01 and **p b 0.001 vs. baseline, &p b 0.05, #p b 0.01 and ##p b 0.001 vs. patients in the febuxostat group at 12months, or the percent change from baseline after 12months.
Data are expressed as the mean ± SD, or medians (interquartile range), the values in parentheses represent the percent changes from baseline after 12 months.
BP: blood pressure, NYHA: New York Heart Association, LVEF: left ventricular ejection fraction, eGFR: estimated glomerular ﬁltration rate, Cr: creatinine, BNP: B-type natriuretic peptide,
hsCRP: high sensitivity C-reactive protein, LDL: low-density lipoprotein, HDL: high-density lipoprotein, MCP: monocyte chemoattractant protein, EPA: eicosapentaenoic acid, AA:
arachidonic acid and ADMA: asymmetric dimethyl arginine.
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vs. −2.3%, p = 0.085, Table 2). In addition, the LV mass index in the
febuxostat group signiﬁcantly decreased after 12 months of treatment
(from 112.5 ± 21.0 g/m2 to 104.2 ± 18.8 g/m2, p b 0.001), whereas it
remained unchanged after 12 months in the allopurinol group (from
109.2 ± 19.6 g/m2 to 105.9 ± 17.3 g/m2, p = 0.116).
During amedian follow-upof 23.0months (range: 13 to 47months),
cardiac events, including two cardiac deaths and three readmissions
due to a worsening of CHF, occurred in ﬁve of the 30 patients (16.7%)
who received allopurinol, whereas cardiac events (two readmissions
for worsening of CHF) were observed in only two of the 31 patients
(6.5%) who received febuxostat (hazard ratio (HR): 0.283, 95% conﬁ-
dence interval (CI) 0.055–1.469, p = 0.283). The Kaplan–Meier esti-
mates of the survival curves are shown in Fig. 3. These data indicate
that a similar incident rate of cardiac events was observed in the two
groups during the follow-up period (log-rank 2.562, p = 0.109, Fig. 3).Table 3
Changes in the blood chemistry parameters and left ventricular ejection fraction (LVEF) in pat
Baseline 3 M
Uric acid (mg/dL)
Febuxostat 9.4±0.5 6.0 ±
Allopurinol 9.3±0.5 6.5 ±
SBP (mm Hg)
Febuxostat 125±10 124
Allopurinol 126±9 124
Heart rate (beats/min)
Febuxostat 75±5 73 ±
Allopurinol 74±5 72 ±
eGFR (mL/min/1.73 m2)
Febuxostat 55.9±10.2 56.6
Allopurinol 58.8±10.6 57.3
Cystatin-C (mg/L)
Febuxostat 1.50±0.32 –
Allopurinol 1.43±0.36 –
Urinary albumin (μg/mg·Cr)
Febuxostat 190.6±162.7 –
Allopurinol 199.6±161.0 –
LVEF (%)
Febuxostat 35.9±7.3 –
Allopurinol 38.4±5.9 –
Data are expressed as the mean ± SD, $p b 0.05, *p b 0.01 and **p b 0.001 vs. baseline #p b 0.0
estimated glomerular ﬁltration rate, Cr: creatinine and LVEF: left ventricular ejection fraction.In addition, the two patients with cardiac death in the allopurinol
group died from a worsening of CHF due to severe pump failure. None
of the patients received percutaneous coronary intervention, coronary
artery bypass grafting or implantable cardiovascular deﬁbrillator treat-
ment during the follow-up period. In addition, none of the patients de-
veloped unstable angina, acute myocardial infarction or sudden death
during the follow-up period.
3.4. Changes in the body mass index, hsCRP levels and lipid proﬁles from
baseline at 12 months in patients treated with febuxostat and allopurinol
The BMI, hsCRP levels and lipid proﬁles at baseline were similar be-
tween the groups, and the percent changes in the BMI and lipid proﬁles
from baseline to 12 months were comparable between the two groups
(Tables 1 and 2). However, a greater decrease in the hsCRP levels from
baseline to 12 months was observed in the patients treated withients treated with febuxostat and allopurinol.
onths 6 Months 12 Months
0.4** 5.7±0.5** 5.6±0.5**
0.6**,## 6.3±0.5**,# # 6.2±0.5**,# #
± 10* 122±9* 122±10*
± 9** 125±9* 123±9*
5* 71±5* 67±7**
4 72±4 71±5$,#
± 11.1 56.4±11.3 56.7±12.0
± 12.7 56.7±13.5 56.5±14.6
1.50±0.37 1.49±0.40
1.52±0.47$ 1.54±0.51$
156.9±149.1** 134.1±125.5**
191.3±164.5 199.5±178.1
36.8±7.3* 41.7±7.6**
37.8±6.3 38.8±8.2
5 and ##p b 0.001 vs. patients in the febuxostat group, SBP: systolic blood pressure, eGFR:
Fig. 2. The changes in the left ventricular ejection fraction (LVEF) from baseline to 12 months after the initiation of treatment in the patients treated with febuxostat and allopurinol. The
LVEF values signiﬁcantly improved in the patients treatedwith febuxostat (febuxostat group, left panel) after 12months of treatment (p b 0.001) and remained unchanged in the patients
treated with allopurinol (allopurinol group, right panel) after 12 months (p = 0.731).
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p = 0.004, Table 2). In both groups, the hsCRP, total cholesterol and tri-
glyceride valueswere signiﬁcantly decreased after 12months (Table 2);
however, the BMI, HDL and low-density (LDL) cholesterol levels were
unchanged after 12 months (Table 2).3.5. The relationships between the changes in the SBP, UA, BNP, ADMA and
MCP-1 levels and the LVEF from baseline to 12months after the initiation of
treatment
The percent change in the LVEF from baseline to 12months in the al-
lopurinol groupwas signiﬁcantly and inversely associated with the per-
cent changes in the serumhsCRP levels (r=−0.662, p b 0.001) and the
plasma ADMA levels (r =−0.586, p = 0.001, Fig. 4C), but not the MCP
levels (r =−0.286, p = 0.126, Fig. 4A). However, the LVEF in the pa-
tients treatedwith allopurinol did not improve after 12months of treat-
ment. In addition, the percent changes in the UA values (r =−0.340,
p= 0.066) and SBP (r= 0.150, p= 0.429) from baselinewas not relat-
ed to the percent change in the LVEF after 12months of treatment (data
not shown).
The LVEF in the febuxostat group signiﬁcantly improved after 12
months of treatment (from 35.79 ± 7.3% to 41.7 ± 7.6%, p b 0.001,Fig. 3. The Kaplan–Meier event-free curves and log-rank tests indicated that the outcomes
of the patients treated with febuxostat and allopurinol were comparable during the fol-
low-up period (log-rank: 2.562, p = 0.109).Fig. 2, Tables 2 and 3). The percent change in the LVEF from baseline
to 12 months in the febuxostat group was signiﬁcantly and inversely
correlated with the percent changes in the serum hsCRP and MCP-1
levels and in the plasma ADMA levels (hsCRP: r =−0.432, p = 0.015,
MCP-1: r = −0.634, p b 0.001, Fig. 4B, ADMA: r = −0.454, p =
0.010, Fig. 4D). Interestingly, the percent changes in the UA values
(r =−0.119, p = 0.522) and SBP (r =−0.039, p = 0.837) from base-
linewere not related to the percent increase in the LVEF after 12months
of treatment (data not shown). These ﬁndings suggest that the im-
provement of the cardiac functionmay be, at least in part, due to reduc-
tions in inﬂammation and improvements in the endothelial function in
CHF patients treated with febuxostat.
3.6. Adverse events
All patients treated with febuxostat and allopurinol tolerated the
treatment well, without any serious side effects during the follow-up
period. None of the patients discontinued the treatment or experienced
any skin disorders, abnormal liver function test results or joint-related
signs or symptoms during the follow-up period.
4. Discussion
Febuxostat and allopurinol are novel non-purine selective inhibitors
of XO that have been shown to attenuate the production of MCP-1 in
monocytes and reduce the LV mass in patients with hypertension and
ischemic heart disease [20–23,25,28–30]. These previous studies sug-
gest that both febuxostat and allopurinol may confer beneﬁts for pa-
tients with CHF and hyperuricemia. However, no previous studies
have performed a direct comparison between febuxostat and allopuri-
nol on inﬂammation and the cardiac function in CHF patients with
hyperuricemia.
The present study provides evidence that febuxostat treatment sig-
niﬁcantly lowers the UA levels, as well as achieves signiﬁcantly higher
percent decreases in theUA, hsCRP,MCP-1 andADMA levels, frombase-
line than allopurinol without inducing any severe adverse effects.
We have previously shown that signiﬁcant positive correlations are
observed between the serum MCP-1 and ADMA levels, and these
markers are also signiﬁcantly and negatively correlated with the EPA/
AA ratio. In addition, the LVEF was signiﬁcantly and positively associat-
ed with the EPA/AA ratio, while it was negatively correlated with the
MCP-1 and ADMA levels [31]. These data suggest that inﬂammation as-
sociated with endothelial dysfunction plays a signiﬁcant role in the
Fig. 4. The relationships between the percent change in the LVEF from baseline to 12 months and the percent changes in the monocyte chemoattractant protein (MCP)-1 level in the al-
lopurinol group (A) and febuxostat group (B) and the asymmetric dimethylarginine (ADMA) levels in the allopurinol group (C) and febuxostat group (D). The percent change in the LVEF
from baseline was signiﬁcantly and inversely related to the percent change in the ADMA levels (C) but not theMCP-1 levels (A) in the allopurinol group. However, the percent change in
the LVEF from baseline was signiﬁcantly and negatively associated with the percent changes in the MCP-1 (B) and ADMA levels (D) in the febuxostat group.
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associated with inﬂammation, endothelial dysfunction and cardiac
function in patients with CHF [31]. The present study showed that
febuxostat signiﬁcantly increased the EPA/AA ratio, and increased it
more than allopurinol (Table 2). Taken together, these ﬁndings indicate
that febuxostat is more effective than allopurinol in reducing inﬂamma-
tion and improving the endothelial function.
In addition, the percent change in CysC from baseline to 12 months
was signiﬁcantly higher in the allopurinol group than that in the
febuxostat group. Furthermore, the percent decrease in the Ualb from
baseline to 12 months was signiﬁcantly higher in the febuxostat group
than that in the allopurinol group, indicating that febuxostat has a supe-
rior renoprotective effect compared to allopurinol (Tables 2 and 3).
Finally, the present study provides the ﬁrst evidence that febuxostat
treatment signiﬁcantly improves cardiac function, but allopurinol does
not. In addition, the percent change in the LVEF from baseline to 12
months in the febuxostat groupwas signiﬁcantly and inversely correlat-
edwith the percent changes in the hsCRP,MCP-1 andADMA levels from
baseline. Interestingly, the percent changes in the UA values and SBP
from baseline were not related to the percent change in the LVEF after
12 months of treatment (Table 3). These ﬁndings suggest that the im-
provement of cardiac functionmay be, at least in part, due to reductions
in inﬂammation and improvements in the endothelial function in CHF
patients treated with febuxostat.
4.1. The association between UA and incident heart failure
It has been proposed that higher serum levels of UA may provide a
selective advantage in the evolution of hominids due to antioxidant
effects [32]. However, hyperuricemia is associated with an increased
risk of hypertension, diabetes, ischemic heart disease and heart failure
[2–4,33,34]. In addition, an elevated serum UA level is signiﬁcantlyassociated with an increased risk of adverse outcomes in patients with
CHF [4,35].
Recent experimental and clinical studies suggest that there is a direct
pathophysiological role for increased XO activity and hyperuricemia in
the progression of CHF [4,36]. In addition, hyperuricemia is associated
with the downregulation of nitric oxide (NO) in endothelial smooth
muscle through an increase in reactive oxygen species (ROS) [37]. The
ROS reduce the bioavailability of endothelial NO and lead to endothelial
dysfunction [11]. Sautin et al. [38] showed that UA induced the activa-
tion of NADPH oxidase followed by the activation of redox-dependent
proinﬂammatory signaling via protein kinase p38.
Another potential pathophysiological link between hyperuricemia
and CHF might be through inﬂammation [39]. Inﬂammation plays an
important role in the pathogenesis of CHF. MCP-1 has been implicated
in the pathogenesis and progression of heart failure as a mediator of
myocardial dysfunction and remodeling [5–7]. Furthermore, the myo-
cardial MCP-1 level is upregulated in rats with volume-overload heart
failure, suggesting thatMCP-1 plays important roles in the pathogenesis
and exacerbation of CHF [8]. The activation ofMCP-1 inducesmonocyte-
mediated inﬂammation, as well as the production of adhesion
molecules and inﬂammatory cytokines, thus resulting in endothelial
dysfunction [10].
Recent studies have shown that UA stimulates the production of
MCP-1 in vascular smooth muscle cells via the activation of the MAPK
and COX-2 pathways [9]. Therefore, UA itself may play a signiﬁcant
role in the pathogenesis and development of CHF.
4.2. Impact of XO inhibition on heart failure
XO is the rate-limiting enzyme in the purine degradation pathway
that catalyzes the ﬁnal two steps in the conversion of adenosine to UA
[20,21]. Several studies have shown that the purine analog XO
53A. Nakagomi et al. / IJC Metabolic & Endocrine 8 (2015) 46–55inhibitors, allopurinol or oxypurinol, can improve the LV function in
the failing heart, prevent myocardial infarct-induced LV remodeling
and reverse LV remodeling in animals with dilated cardiomyopathy
[36,40–43]. In addition, intravenous administration of allopurinol acute-
ly improves the ATP energy delivery in failing human hearts [24].
However, Hare et al. showed that oxypurinol did not lead to clinical
improvements in 405 unselected patients with moderate to severe CHF
at 24 weeks [44]. However, a post-hoc analysis suggested that patients
with elevated UA levels (N9.5 mg/dL) might represent a responsive
group, as there was a trend towards a beneﬁt in patients who received
oxypurinol in this subgroup. The response to oxypurinol, as indicated
by the serum UA reduction, correlated with the degree of the clinical
outcome in the high serum UA group. These data suggest that the
serum UA levels may serve as a valuable biomarker to target XO inhibi-
tion for select patients with CHF [44]. More recently, Givertz et al.
showed that allopurinol failed to improve the clinical status, exercise ca-
pacity, quality of life, or LVEF after 24 months of treatment in 253 CHF
patients with hyperuricemia [45].
Febuxostat is a potent non-purine-selective inhibitor of XO that ex-
hibits anti-hyperuricemic activity by reducing the formation of UA.
Febuxostat has been shown to potently inhibit both the oxidized and re-
duced forms of XO [46]. In contrast to allopurinol, febuxostat provides a
more selective and potent inhibition of XOandprovidesmore persistent
enzyme inhibition and greater hypouricemic activity. In addition,
febuxostat is excreted primarily by the liver, whereas allopurinol is ex-
creted by the kidney [46]. These data may support the previous clinical
ﬁndings that the serum UA-lowering efﬁcacy of febuxostat is greater
than that of allopurinol in patients with hyperuricemia, irrespective of
the presence or absence of CKD [18,20,21].
Recent studies have shown that febuxostat improved the LV func-
tion in pacing-induced CHF in dogs [47] and attenuated systolic
overload-induced LV hypertrophy and dysfunction in mice [25]. More
recently, Sezai et al. [30] showed that febuxostat was more effective
than allopurinol in reducing the UA levels and decreasing the LV mass
in cardiac surgery patients with hyperuricemia. In addition, they also
showed that febuxostat had a renoprotective effect and inhibited oxida-
tive stress in these patients.
4.3. The mechanisms underlying the beneﬁcial effects of febuxostat
treatment in CHF patients with hyperuricemia
The mechanisms responsible for the beneﬁcial effects of febuxostat
treatment in the present study remain unclear. However, anti-
inﬂammatory effects and improvements in the endothelial function,
the prevention of myocardial remodeling and renoprotective effects,
as well as the combination of these effects, may play important roles
in the treatment of CHF with hyperuricemia.
The present study showed that febuxostat attenuates the serum
levels of MCP-1 and hsCRP. These data indicate that febuxostat treat-
ment reduces inﬂammation in CHF patients with hyperuricemia. The
production of proinﬂammatory cytokines and chemokines is regulated
by NF-κB and MAPK, which is activated in patients with CHF [48].
Febuxostat therapy prevents lipopolysaccharide-induced MCP produc-
tion via MAPK phosphatase-1 [22].
In addition, the present study showed that the LVEF improved after
12months of treatment in the patientswho received febuxostat, but not
in those that received allopurinol. The percent increase in the LVEF from
baseline to 12 months was signiﬁcantly associated with the percent de-
creases in the MCP and hsCRP levels in the CHF patients treated with
febuxostat. These anti-inﬂammatory effects of febuxostat may play a
signiﬁcant role in improving the cardiac function in CHF patients with
hyperuricemia.
The present study also demonstrated that febuxostat reduces the
plasma level of ADMA, an endogenous and competitive inhibitor of
NO, indicating that treatment with febuxostat may improve the endo-
thelial function in CHF patients with hyperuricemia. In addition, in thepresent study, the percent increase in the LVEF frombaselinewas signif-
icantly associated with the percent decrease in the ADMA level in CHF
patients who received febuxostat. These data indicate that febuxostat
treatment may improve the cardiac function, at least in part, due to
improvements in the endothelial function in CHF patients with
hyperuricemia.
Taken together, these ﬁndings indicate that febuxostat treatment
may improve cardiac function, at least in part, due to reductions in in-
ﬂammation and improvements in the endothelial function in CHF pa-
tients with hyperuricemia.
Xu et al. [25] showed that febuxostat attenuated systolic overload-
induced LV hypertrophy. Sezai et al. [30] reported that febuxostat, but
not allopurinol, reduced the LV mass index in cardiac surgery patients
with hyperuricemia. The present study showed that the LV mass
index in the febuxostat group signiﬁcantly decreased after 12 months
of treatment, whereas it remained unchanged after 12months in the al-
lopurinol group (Table 2). These data suggest that febuxostat may pre-
vent the progression of LV remodeling in patients with ischemic heart
disease, hypertension and CHF.
The present study showed that the percent decrease in the eGFR
from baseline to 12 months was signiﬁcantly higher in the allopurinol
group than that in the febuxostat group (Table 2). In addition, the per-
cent increase in the CysC level from baseline to 12 months was signiﬁ-
cantly higher in the allopurinol group than that in the febuxostat
group (Tables 2 and 3). The CysC levels after 12 months of treatment
in the allopurinol group signiﬁcantly increased compared to those at
baseline (Table 3). Furthermore, the percent decrease in the Ualb levels
from baseline to 12 months was signiﬁcantly higher in the febuxostat
group than that in the allopurinol group (Tables 2 and 3). These data
suggest that febuxostat treatment is superior to allopurinol in terms of
the renoprotective effect in patients with CHF and hyperuricemia.
Taken together, the anti-inﬂammatory effects, improvements in the
endothelial function, the prevention of myocardial remodeling and
renoprotective effects, as well as the combination of these effects, may
play important roles in the treatment of CHF with hyperuricemia.
4.4. Effects of febuxostat and allopurinol on the NYHA class and outcomes
The prevalence of NYHA class at baseline and at 12monthswas sim-
ilar between the two groups. However, after 12 months, some patients
who received allopurinol appeared to have a worsening clinical status,
whereas patients treated with febuxostat had a functional improve-
ment. In addition, compared with the initial NYHA class, these changes
were statistically signiﬁcant in the febuxostat group, but not in the allo-
purinol group (Table 2).
The present study showed that during the median follow-up of 23.0
months (range: 13 to 47months), cardiac events occurred in ﬁve of the
30 patients who received allopurinol, whereas cardiac events were ob-
served in only two of the 31 patients who received febuxostat (HR:
0.283, 95%CI 0.055–1.469, p=0.283). In addition, the Kaplan–Meier es-
timates of the survival curves (Fig. 3) indicate that a similar incident rate
of cardiac events was observed in the patients treated with febuxostat
and allopurinol during the follow-up period.
All eligible patients had received standardmedical treatment, includ-
ing ACEIs, ARBs, β-blockers, furosemide, spironolactone or any combina-
tion thereof for at least three years prior to enrollment in the present
study. At baseline, the prevalence of the use of these medications was
comparable between the two groups. In addition, the concomitant med-
ications were not changed during the follow-up period. Therefore, the
concomitant medications do not appear to contribute to the changes in
the NYHA class or the outcomes in patientswith CHF and hyperuricemia.
4.5. Study limitations
There are several potential limitations associated with the present
study. The most signiﬁcant limitation is the fact that the sample size
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ceiving the recommended allopurinol dose of 100mg, the endpoint of a
serumUA level b6.0mg/dLwas not achieved. Third, this studywas only
12months in duration, whichmay not have been long enough to deter-
mine the effects of medications on inﬂammation, the cardiac function
and the outcomes. Fourth, patients with CHF had received ACEIs,
ARBs, β-blockers, furosemide or spironolactone for at least three years
before enrollment, and patients in the acute decompensated stage of
CHF were excluded. Therefore, all of the eligible patients in the present
study were stabilized with standard treatment before enrollment, thus
suggesting that oxidative stress or inﬂammation may have already
been inhibited, and the effects of febuxostat and allopurinol on inﬂam-
mation and the cardiac function may differ in unstable patients. Finally,
we did not measure the endothelial function assessed by reactive hy-
peremia with peripheral arterial tonometry.
5. Conclusion
In conclusion, after 12months of treatment, febuxostat was superior
to allopurinol in reducing the UA levels. In addition, febuxostat achieved
signiﬁcantly higher percent decreases in the UA and MCP-1 levels from
baseline than those in allopurinol. The LVEF in both groups improved
after 12 months; however, a greater percent increase in the LVEF from
baselinewas observed in the febuxostat group than that in the allopuri-
nol group. The percent increase in the LVEF from baseline was found to
be signiﬁcantly associated with the percent decreases in MCP-1 and
hsCRP in the febuxostat group.
These data indicate that febuxostat ismore effective than allopurinol
in reducing theUA level and inﬂammation andmay improve the cardiac
function in CHF patients with hyperuricemia, at least in part due to re-
ductions in inﬂammation and improvements in endothelial dysfunc-
tion. Further studies are needed to elucidate the exact mechanisms
involved in this pathophysiological pathway and to develop optimal
therapeutic strategies for suppressing the deterioration of CHF patients
with hyperuricemia.
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